Clinical analysis of rectal neuroendocrine carcinoma:a report of 16 cases.
- Author:
Yi-fan PENG
1
;
Wei-cheng XUE
;
Jin GU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Carcinoma, Neuroendocrine; drug therapy; pathology; surgery; Chemotherapy, Adjuvant; Female; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Rectal Neoplasms; drug therapy; pathology; surgery; Retrospective Studies; Survival Rate; Young Adult
- From: Chinese Journal of Gastrointestinal Surgery 2009;12(2):170-173
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the clinical data and surgical treatment strategy of rectal neuroendocrine carcinoma (NEC).
METHODSSixteen cases of rectal NEC and 222 cases of rectal carcinomas receiving surgical treatment in Beijing Cancer Hospital from 2003 to 2007, were analyzed retrospectively.
RESULTSAmong the 16 rectal NEC patients, 4(25%) received Miles surgery, 7(43.8%) Dixon surgery, 2 combined multiple organ resection and 3 local resection. Lymph note metastases occurred in 11 cases(68.8%) and distant metastases in 7 cases (43.8%). Among the 222 rectal carcinoma patients, 43(19.4%) received Miles surgery, 152(68.5%) Dixon surgery, 12 palliative operation, 6 colostomy and 9 just received laparotomy. Lymph note metastases occurred in 125 cases (56.3%). In rectal NEC group, postoperative 1-, 2- and 3-year survival rates were 62.5%, 25.0% and 0.63% respectively, which were significantly lower than 83.1%, 61.7% and 46.1% in rectal carcinoma group(all P<0.01).
CONCLUSIONSRectal NEC is a rare disease. More vascular invasion, lymph node and distant organ metastases are found in rectal NEC than rectal carcinoma, and the prognosis of rectal NEC is worse than rectal cancer.
